-
Media Release
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
-
Media Release
Media Statement: Leading US cardiology societies strongly recommend Entresto® as a new standard of care treatment in an earlier-than-expected joint update of clinical practice guidelines for heart failure
-
Media Release
Media Statement: FortiHFy Global Clinical Program for Entresto®
-
Media Release
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
-
Media Release
Largest global psoriasis survey shows 85% of U.S. respondents faced social stigma like discrimination and humiliation because of their skin
-
Media Release
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
-
Media Release
Novartis data show Gilenya® had significantly greater patient retention compared to iDMTs in relapsing-remitting MS
-
Media Release
Novartis BAF312 reduced the risk of disability progression in pivotal phase III study in secondary progressive MS patients
-
Media Release
Novartis data finds relapsing MS patients on Gilenya® had greater treatment retention and satisfaction rates vs. injectable DMTs
-
Media Release
Novartis announces FDA approval of Xolair® (omalizumab) for pediatric allergic asthma
-
Media Release
Novartis late-breaking data show Cosentyx® continues to deliver high skin clearance for majority of psoriasis patients at four years
-
Media Release
Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions